How Much Can we Rely on Human Cell-Based Immune Systems to Support & Implement Caveats of New Therapeutic Approaches?
Time: 3:15 pm
day: Conference Day One
Details:
- Reviewing a case study for in vitro systems to apply, move on and stratify patients to optimize drug development
- Exploring design for discovery, first in human and early clinical studies to meet expectations and requirements from the regulators following the FDA modernization act for IND and BLA approvals
- Exploring alignment of phenotypic changes, secretory and inflammatory responses in FTD modelling vs human data
